MicroRNA in ischemic stroke etiology and pathology.
Small, noncoding, microRNAs (miRNAs) have emerged as key mediators of posttranscriptional gene silencing in both pathogenic and pathological aspects of ischemic stroke biology. In stroke etiology, miRNA have distinct expression patterns that modulate pathogenic processes including atherosclerosis (miR-21, miR-126), hyperlipidemia (miR-33, miR-125a-5p), hypertension (miR-155), and plaque rupture (miR-222, miR-210). Following focal cerebral ischemia, significant changes in the miRNA transcriptome, independent of an effect on expression of miRNA machinery, implicate miRNA in the pathological cascade of events that include blood brain barrier disruption (miR-15a) and caspase mediated cell death signaling (miR-497). Early activation of miR-200 family members improves neural cell survival via prolyl hydroxylase mRNA silencing and subsequent HIF-1α stabilization. Pro- (miR-125b) and anti-inflammatory (miR-26a, -34a, -145, and let-7b) miRNA may also be manipulated to positively influence stroke outcomes. Recent examples of successfully implemented miRNA-therapeutics direct the future of gene therapy and offer new therapeutic strategies by regulating large sets of genes in related pathways of the ischemic stroke cascade.
Rink
Cameron
C
Department of Surgery, The Ohio State University Medical Center, Columbus, Ohio, USA.
Khanna
Savita
S
D000818:Animals; D006801:Humans; D020925:Hypoxia-Ischemia, Brain / Q000453:epidemiology / Q000209:etiology* / Q000235:genetics / Q000628:therapy; D015994:Incidence; D035683:MicroRNAs / Q000235:genetics / Q000502:physiology*; D008954:Models, Biological; D058990:Molecular Targeted Therapy / Q000379:methods; D020521:Stroke / Q000453:epidemiology / Q000209:etiology* / Q000235:genetics / Q000628:therapy
D035683:MicroRNAs